Document is current

Article History

Received: 14 October 2022

Accepted: 18 January 2023

First Online: 23 March 2023

Declarations

:

: For ILD and non-ILD tissue sections analysed by IHC, informed consent and local ethics approval was obtained from South East Scotland SAHSC Bioresource and the MRC Nottingham Molecular Pathology Node respectively. For non-IPF and IPF HLFs, cells were isolated from patient lung tissue following informed consent and local ethics approval from the MRC Nottingham Molecular Pathology Node. For normal adjacent lung tissue (NAT) and IPF lung tissue used for PCLS, informed consent and local ethics approval was obtained from the NRES Committee East of England. All animal studies were approved by the University of Nottingham Animal Welfare and Ethical Review Board, carried out in accordance with the Animals (Scientific Procedures) Act 1986 and planned and reported in compliance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines.

: Not applicable.

: AstraZeneca partially funded this study and participated in the study design, data collection, data analysis and data interpretation. K.E.S, AK, C.E.H, C.L.O and E.S.C, are employees of AstraZeneca and hold stock or stock options. R.G.J has received grants, contracts or consultancy fees from AstraZeneca, Biogen, Galecto, GlaxoSmithKline, RedX, Pliant, Genetech, Bristol Myers Squibb, Daewoong, Veracyte, Resolution Therapeutics, Boehringer Ingelheim, Chiesi, Roche, patientMpower, Galapagos and Vicore and has non-financial advisory and leadership roles for NuMedii and Action for Pulmonary Fibrosis respectively. The remaining authors declare no competing interests.